Effectiveness of Heterologous and Homologous Ad26.COV2.S Vaccine Boosting in Preventing COVID-19-Related Outcomes Among Individuals with a Completed Primary Vaccination Series in the United States

<b>Background/Objectives:</b> COVID-19 vaccines have significantly reduced the mortality and morbidity associated with SARS-CoV-2. In the fall of 2021, the U.S. Food and Drug Administration amended its emergency use authorization guidelines for COVID-19 vaccines to allow the administrati...

Full description

Bibliographic Details
Published in:	Vaccines
Main Authors:	Mawuli Nyaku, Lara S. Yoon, Deborah Ricci, Lexie Rubens, Paige Sheridan, Monica Iyer, Thomas Zhen, Raymond A. Harvey, Ann Madsen
Format:	Article
Language:	English
Published:	MDPI AG 2025-02-01
Subjects:	COVID-19 adenovirus vaccine booster vaccine real-world data real-world evidence
Online Access:	https://www.mdpi.com/2076-393X/13/2/166

Similar Items

An observational post-authorization study to assess the effectiveness of a single dose Ad26.COV2.S for the prevention of COVID-19 using real-world data
by: Amelia Boehme, et al.
Published: (2024-12-01)

Did We Overreact? Insights on COVID-19 Disease and Vaccination in a Large Cohort of Immune-Mediated Inflammatory Disease Patients during Sequential Phases of the Pandemic (The BELCOMID Study)
by: Jeroen Geldof, et al.
Published: (2024-10-01)

Real-Time Survey of Vaccine Safety of the mRNA-1273 SARS-CoV-2 Vaccine in Workplace Vaccination at Keio University
by: Kaho Okumura, et al.
Published: (2022-09-01)

Immunogenicity and Safety of Homologous and Heterologous Prime–Boost Immunization with COVID-19 Vaccine: Systematic Review and Meta-Analysis
by: Haoyue Cheng, et al.
Published: (2022-05-01)

Comparative Safety and Effectiveness of Heterologous CoronaVac–ChAdOx1 versus Homologous CoronaVac Vaccination in a Real-World Setting: A Retrospective Cohort Study
by: Ayakarn Ruenkham, et al.
Published: (2023-09-01)

Comparison of antibody responses of heterologous and homologous Covid-19 booster vaccination: an observational study
by: Nayab Batool Rizvi, et al.
Published: (2024-11-01)

Age and Gender Disparities in Adverse Events Following COVID-19 Vaccination: Real-World Evidence Based on Big Data for Risk Management
by: Xiaomo Xiong, et al.
Published: (2021-07-01)

Influenza Vaccination Effectiveness in Paediatric ‘Healthy’ Patients: A Population-Based Study in Italy
by: Anna Cantarutti, et al.
Published: (2022-04-01)

Comparison of Safety of Different Vaccine Boosters Following Two-Dose Inactivated Vaccines: A Parallel Controlled Prospective Study
by: Zhi-Qiang Lin, et al.
Published: (2022-04-01)

Cell-based influenza vaccines: An effective vaccine option for under 60-year-olds
by: Gärtner, Barbara C., et al.
Published: (2024-04-01)

Safety and Immunogenicity of Homologous Recombinant Adenovirus Type 5-Vectored COVID-19 Vaccine Booster Dose in Healthy Adults Aged 18–60 Years: a Single-Center, Open-Label Trial
by: Siyue Jia, et al.
Published: (2023-12-01)

Antibody Response after Homologous and Heterologous Prime–Boost COVID-19 Vaccination in a Bangladeshi Residential University Cohort
by: Nihad Adnan, et al.
Published: (2024-04-01)

Comparing Antibody Responses to Homologous vs. Heterologous COVID-19 Vaccination: A Cross-Sectional Analysis in an Urban Bangladeshi Population
by: Kazi Istiaque Sanin, et al.
Published: (2025-01-01)

Real-world safety of HPV vaccines over 18 y: A comprehensive analysis of U.S. VAERS reports
by: Yonglong Su, et al.
Published: (2025-12-01)

Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection
by: Hakjun Hyun, et al.
Published: (2023-03-01)

Mix-and-Match COVID-19 Vaccinations (Heterologous Boost): A Review
by: Ishan Garg, et al.
Published: (2022-07-01)

Heterologous versus homologous COVID-19 booster vaccinations for adults: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials
by: Mark Aninakwah Asante, et al.
Published: (2024-06-01)

Human Papillomavirus Vaccine Impact and Effectiveness in Six High-Risk Populations: A Systematic Literature Review
by: Elizabeth Goodman, et al.
Published: (2022-09-01)

Real-world evidence of quadrivalent meningococcal conjugate vaccine safety in the United States: a systematic review
by: Tracy a Becerra-Culqui, et al.
Published: (2021-05-01)

Association between Reactogenicity and Immunogenicity in a Vaccinated Cohort with Two mRNA SARS-CoV-2 Vaccines at a High-Complexity Reference Hospital: A <em>Post Hoc</em> Analysis on Immunology Aspects of a Prospective Cohort Study
by: Joaquín Sáez-Peñataro, et al.
Published: (2024-06-01)

Effectiveness and Safety of the MVA–BN Vaccine against Mpox in At-Risk Individuals in the United States (USMVAc)
by: Soowoo Back, et al.
Published: (2024-06-01)

Assessment of COVID-19 vaccine effectiveness in a nation with a low vaccination coverage: insights from real-world data and propensity score matched analyses
by: George Dimitrov, et al.
Published: (2024-12-01)

Differences in the Expression Levels of SARS-CoV-2 Spike Protein in Cells Treated with mRNA-Based COVID-19 Vaccines: A Study on Vaccines from the Real World
by: Luigi Cari, et al.
Published: (2023-04-01)

Patients with post-COVID-19 vaccination facial palsy: To boost or not to boost?
by: Cirillo Nicola, et al.
Published: (2022-08-01)

COVID-19 Vaccine Booster: To Boost or Not to Boost
by: Rahul Shekhar, et al.
Published: (2021-10-01)

Investigation of Adverse Events Experienced by Healthcare Workers following Immunization with Homologous or Heterologous COVID-19 Booster Vaccinations
by: Yunhua Wei, et al.
Published: (2022-11-01)

Comparison of humoral immune response in heterologous and homologous COVID-19 booster vaccine groups using CoronaVac and mRNA-based BNT162b2 vaccines
by: Serkan Atıcı, et al.
Published: (2023-07-01)

Analyzing real-world data to understand COVID-19 vaccination effects on hospitalization rates in patients with solid malignancies
by: George Dimitrov, et al.
Published: (2023-03-01)

Real-world effectiveness of varicella vaccination in Guangzhou, China, 2017–2022: a matched case-control analysis
by: Junxi Li, et al.
Published: (2025-12-01)

SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines
by: Camilo C. Roa, et al.
Published: (2024-12-01)

Brand-specific estimates of influenza vaccine effectiveness for the 2021–2022 season in Europe: results from the DRIVE multi-stakeholder study platform
by: Anke L. Stuurman, et al.
Published: (2023-07-01)

PRRSV GP4 subunit vaccine combined with adenovirus heterologous prime-boost immunization strategy induced a significant immune response in mice
by: Honghuan Li, et al.
Published: (2025-05-01)

A Comparative Analysis of COVID-19 Vaccines Based on over 580,000 Cases from the Vaccination Adverse Event Reporting System
by: Kathleen Gallo, et al.
Published: (2022-03-01)

The Platform trial In COVID-19 vaccine priming and BOOsting (PICOBOO) booster vaccination substudy protocol
by: McLeod C, et al.
Published: (2024-11-01)

Willingness of college students to receive COVID-19 heterologous vaccination in Taizhou, China
by: Hui Shao, et al.
Published: (2023-01-01)

Heterologous Immunity and Hepatitis C Virus: Impact on Natural Infection, Pathogenesis and Vaccine Design
by: Babita Agrawal, et al.
Published: (2020-06-01)

Long-Term Effects of Human Papillomavirus Vaccination in Clinical Trials and Real-World Data: A Systematic Review
by: Megumi Kurosawa, et al.
Published: (2022-02-01)

Research on Application of Medical Device Real-World Evidence in Regulatory Decisions of the United States
by: Xiaofang GU, et al.
Published: (2025-07-01)

Non-pharmaceutical interventions in containing COVID-19 pandemic after the roll-out of coronavirus vaccines: a systematic review
by: Xiaona He, et al.
Published: (2024-06-01)

Who is getting boosted? Disparities in COVID-19 vaccine booster uptake among health care workers
by: Wigdan Farah, et al.
Published: (2023-04-01)